IP Library Granted Patent US 8,022,234
Granted Patent B2
US 8,022,234 · App. 12/571,060 · Granted Sep 20, 2011

Compounds and compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,022,234
App. No.
12/571,060
Granted
Sep 20, 2011
Kind
B2
Abstract

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Claims (28)

1. A pharmaceutical formulation comprising one or more excipients and a compound having the structure

wherein

R 1 and R 4 independently are —OH, an ester or an ether;

R 2 is —H, —OH, an ester or an ether

R 3 is —OH, an ester, an ether or halogen; and

R 8 is —O— or —CHR 10 — wherein R 10 is —OH.

2. The formulation of claim 1 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.

3. The formulation of claim 2 wherein the compound has the structure

4. The formulation of claim 2 wherein the compound has the structure

5. The formulation of claim 3 wherein the compound has the structure

6. The formulation of claim 5 wherein R 1 , R 2 and R 4 are —OH and R 3 is —OH or —Br.

7. The formulation of claim 1 wherein the formulation is for oral administration.

8. The formulation of claim 6 wherein the formulation is for oral administration.

9. A compound having the structure

wherein

R 1 , R 2 and R 4 independently are —OH, an ester or an ether;

R 3 is —OH, an ester, an ether or halogen

R 5 is —CH 3 or —CH 2 OH; and

R 6 is —H, —CH 3 or —CH 2 OH.

10. The compound of claim 9 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.

11. The compound of claim 10 wherein R 5 is —CH 3 .

12. The compound of claim 11 wherein R 6 is —H or —CH 3 .

13. The compound of claim 10 wherein the compound has the structure

14. The compound of claim 10 wherein the compound has the structure

15. The compound of claim 13 wherein the compound has the structure

16. The compound of claim 15 wherein R 1 , R 2 and R 4 are —OH and R 3 is —OH or Br.

17. The compound of claim 16 wherein the compound has the structure

18. The formulation of claim 6 wherein the compound has the structure

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
CHANGE OF NAME Recorded Mar 11, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024066/0325 →